EMERGING RESEARCHER APPOINTED TO JAMES PACKER CHAIR IN MOOD DISORDERS AT UNSW Joins department with over 60 years research in Psychiatry and Mental Health to investigate Bipolar Disorder
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney.
Professor Dean spoke about UNSW being home to an outstanding mental health research community with key partners across the Mindgardens Neuroscience Network, welcoming Dr Ratheesh
As a leading clinical researcher in mood and psychotic disorders, Dr Ratheesh is passionate about prompt and early access to interventions for people with such conditions.
The appointment comes after prominent businessman and investor James Packer, jointly with The Packer Family Foundation, made a $7 million gift to establish the role last year.
The Chair will lead a new unit at UNSW and the Mindgardens Neuroscience Network that will conduct rigorous research in mental health, with a particular focus on mood disorders such as bipolar disease. The gift also funds a team of researchers to support the Chair.
Dr Ratheesh’s research is focused on understanding pathways leading to the onset of mood disorders and finding ways to provide effective treatments for individuals who develop such conditions. He has worked as a psychiatrist for over 12 years both in youth and adult mental health settings and has led several studies that have helped identify risk markers for future bipolar disorder.
He believes some of the current knowledge gaps in mood disorders include our ability to predict who will develop such conditions, who is at risk of worsening, and who will respond to specific treatments.
Dr Ratheesh currently leads an NHMRC Partnership grant in early intervention for bipolar disorder and is a chief investigator on a Centre of Research Excellence grant in early intervention for bipolar disorder. He co-leads the International Society of Bipolar Disorders Taskforce on Early Intervention and is an Associate Editor for the leading journal, the Australian and New Zealand Journal of Psychiatry. He has received awards from the International Early Psychosis Association and the Australasian Society for Bipolar and Depressive Disorders for his research.
You Might also like
-
The world of AI avatars in dementia care
Dementia care is one of the critical issues facing the aged care industry. About 500,000 Australians currently live with the brain disorder condition, and this is tipped to rise to 1.1 million in a generation.
How to effectively provide quality care for people living with dementia was a key element of the royal commission into aged care, which found the complex care required was an ongoing challenge for the industry.
-
Allied health flourishes in regional and rural Victoria
Genhealth Hamilton was established in 2015 in regional and rural Victoria. The practice offers a range of services including physiotherapy, podiatry, occupational therapy, exercise science, and group classes such as clinical reformer therapy and clinical Pilates in Hamilton, which has a population of around 10,000. The clinic also serves a wider community within 100 kilometre, reaching rural residents and local industries.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.